Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. We discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). We are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. Our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. Ironwood was founded in 1998 out of the Whitehead Institute for Biomedical Research, an affiliate of Massachusetts Institute of Technology (MIT), and we remain headquartered in the vibrant biotech community of Cambridge, Mass. Each of our roughly 480 employees holds equity in the company, which means we all share the responsibility to help Ironwood succeed. To learn more about what itÍs like to join the Ironwood team, click the ñCareersî tab above or connect with us at www.ironwoodpharma.com or on Twitter at www.twitter.com/ironwoodpharma or www.twitter.com/ironwoodcareers.